Nektar (NKTR) Director Roy Whitfield Receives RSU Award

What Happened
Roy A. Whitfield, a director of Nektar Therapeutics (NKTR), received equity awards on Sept. 23, 2026. The filing shows 2,000 shares acquired as restricted stock units (RSUs) and 4,000 derivative RSU units granted, each at $0.00 (no cash paid). These awards are contingent rights to receive shares upon vesting rather than immediate open-market purchases.

Key Details

• Transaction date: 2026-09-23; Form 4 filed 2026-09-25 (filed within the standard 2-business-day window).
• Awards: 2,000 RSUs (common stock) + 4,000 derivative RSUs; grant price $0.00; total immediate cash value reported = $0.
• Vesting/footnotes: filing notes (F1/F2) that the RSUs are contingent rights to receive one share per RSU and that "this RSU award vests in full one year following Sept. 23, 2026." Footnote F4 also references an option vesting monthly over a one‑year period beginning Sept. 23, 2026.
• Reverse split: amounts have been adjusted for a 1-for-15 reverse stock split effected June 8, 2025 (F3).
• Shares owned following the transaction: not specified in the summary provided.

Context

• These were grants/awards (transaction code A), not open-market purchases or sales, so they do not reflect an immediate buy/sell sentiment and do not provide proceeds to the insider now.
• Derivative RSUs mean Whitfield has a contingent right to receive shares upon vesting; no shares are necessarily issued until vesting conditions are met.
• The filing appears timely (filed two days after the grant). For retail investors, awards are common compensation and may dilute shares when they vest, but they are not direct cash transactions or sales.